Although the therapeutic effect of exogenous PPAR-α agonists such as fenofibrate has previously been studied in a few models of peripheral neuropathy, their potential to prevent paclitaxel-induced peripheral neuropathy (PIPN) has not, to our knowledge, been explored. The gene discussed is PPARA; the disease is peripheral neuropathy.